- Conditions
- Pharmacokinetics
- Interventions
- midomafetamine
- Drug
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 639
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Participants
- Interventions
- Etrumadenant
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Healthy Participants
- Interventions
- TAK-994
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Lincoln, Nebraska
- Conditions
- Neoplasms
- Interventions
- RO5503781, posaconazole
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Dallas, Texas
- Conditions
- Healthy
- Interventions
- 2x500 mg Metformin (Glumetza), 5 mg Linagliptin/1000 mg Metformin FDC, 5 mg Linagliptin (Tradjenta), 3x500 mg Metformin (Glumetza), 2 x 500 mg Metformin (Glumetza), 5 mg Linagliptin/1000mg Metformin FDC, 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Major Depressive Disorder
- Interventions
- CYB003, Psychotherapy, Placebo, Psychological Support
- Drug · Behavioral
- Lead sponsor
- Cybin IRL Limited
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
- Conditions
- Healthy Participants
- Interventions
- Staccato alprazolam, Oral alprazolam
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Interventions
- BMS-986165 Capsule, BMS-986165 Tablet
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Healthy Volunteers
- Interventions
- GDC-0941, rabeprazole
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- South San Francisco, California
- Conditions
- Healthy Volunteer
- Interventions
- Rabeprazole, CC-92480
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Healthy
- Interventions
- Seltorexant High Dose, Seltorexant Low Dose
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy
- Interventions
- divalproex sodium, Depakote®
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Bioavailability
- Interventions
- EPA + DHA Ruby-O, EPA + DHA Krill Oil
- Dietary Supplement
- Lead sponsor
- Midwest Center for Metabolic and Cardiovascular Research
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Port Saint Lucie, Florida
- Conditions
- Healthy
- Interventions
- TP 3654
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Bioavailability
- Interventions
- EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved)
- Dietary Supplement · Other
- Lead sponsor
- Midwest Center for Metabolic and Cardiovascular Research
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Boca Raton, Florida • Chicago, Illinois
- Conditions
- Parkinson's Disease (PD)
- Interventions
- HNC364 Injectable Suspension, Rasagiline Tablets
- Drug
- Lead sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Postmenopausal, Non-lactating, Surgically Sterile
- Interventions
- risedronate
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Miramar, Florida • Austin, Texas
- Conditions
- Healthy
- Interventions
- ACH-0145228: Immediate Release, ACH-0145228: Powder-in-capsule
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Hypogonadism, Hypogonadism, Male
- Interventions
- Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Healthy Volunteers
- Interventions
- Lutikizumab Dose A, Lutikizumab Dose B
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Cypress, California • Grayslake, Illinois • Austin, Texas
- Conditions
- Healthy
- Interventions
- Glimepiride 1mg Tablets
- Drug
- Lead sponsor
- Ranbaxy Laboratories Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- Tivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D, oral
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Fort Myers, Florida • Nashville, Tennessee + 1 more
- Conditions
- HIV Infections
- Interventions
- Fostemsavir 600 mg, Fostemsavir 200 mg
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Healthy
- Interventions
- PF-04958242 capsule, PF-04958242 oral solution
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut